Blockchain

INX and Backed Launch On-Chain Tokenized NVIDIA Stock Trading

Zug, Switzerland, July 2nd, 2024, Chainwire

INX, the regulated marketplace for trading security tokens and tokenized real-world assets, and Backed, a pioneer in real-world asset tokenization, today announced the listing of tokenized stock on the INX platform for eligible non-US users. This groundbreaking partnership begins with the launch of bNVDA, a tokenized security backed one-to-one by NVIDIA Corp (NVDA) stock, issued on the Ethereum network, with the blockchain ledger conveying ownership.

The Future of Investing

This launch is a monumental step towards democratizing access to traditional financial assets and merging them with the 24/7 liquidity and accessibility of the digital asset space. Non-US eligible investors will be able to trade bNVDA with the ease and speed of cryptocurrencies, outside of traditional stock market hours, and with the ability to fund their account with crypto. Self-custodial securities open up new possibilities for traders. This is only the start, with more assets coming in the pipeline, such as ETFs, Bonds, or even commodities arriving on INX in the future. Backed’s tokenized public securities are called bTokens, which are permissionless ERC-20 tokens that can be transferred between wallets freely.

“We are thrilled to have Backed as one of our tokenization and issuance partners, and we’re excited to initiate the listing of their securities in our marketplace.” said Shy Datika, CEO of INX. “This partnership represents another milestone in our journey to enable the trading of real-world assets tokens. We are committed to advancing the accessibility and efficiency of the tokenized asset market, ushering in a new era of global finance.”

Adam Levi, Backed Co-Founder, added, “Crypto traders have been seeking a seamless bridge to the traditional market – and tokenized stocks provide exactly that. bNVDA is just the beginning; we envision a future where investors can build diversified portfolios of tokenized real-world assets directly on the blockchain. No need to offramp, and users can self custody their entire portfolio.”

INX provides a marketplace for tokenized assets and their partnership with Backed brings the first tokenized share to this market. This means that Backed’s bNVDA can now be traded on INX, which integrates crypto, fiat, and security tokens into a unified marketplace. Traders can now benefit from 24/7 availability to trade bNVDA, and fractional share ownership.

Backed’s tokenized assets, including bNVDA, are issued under an EU prospectus, allowing eligible investors to have full transparency of the products. Holders of bNVDA have the primary claim to the collateral value, in this case, Nvidia stock, which is held with a licensed custodian under an account control agreement. Distributed ledgers (blockchains) are the primary way that ownership is defined.

With Republic recently reaffirming its commitment to form a strong partnership with INX, and Backed completing their Series A funding round, the ecosystem for tokenized securities is becoming increasingly exciting. With partnerships like this, true interoperability and composability is becoming a reality.

Key Benefits:

●     Self-Custody: Hold the securities directly in a wallet that only you have control over.

●     24/7 Trading: Trade anytime, anywhere, not limited by traditional market hours.

●     DeFi ready: Use your tokenized stocks as collateral for loans or within other DeFi applications.

●     Blockchain Security: Leverage the inherent security and transparency of blockchain technology.

●     Access: Available to non-US qualified investors across multiple jurisdictions.

●     All On-chain: Fund your account with crypto and invest in tokenized stocks.

How to Get Started

Right now, to trade bNVDA, investors need to create an account on the INX platform and complete the required verification process.

About INX

INX provides regulated trading platforms for digital securities and cryptocurrencies. With the combination of traditional markets expertise and a disruptive fintech approach, INX provides state-of-the-art solutions to modern financial problems. INX is led by an experienced and dedicated team of business, finance, and technology veterans with the shared vision of redefining the world of capital markets via blockchain technology and a disciplined regulatory approach

In a world where anything can be tokenized on a blockchain network, INX provides an innovative, regulated marketplace for trading these security tokens, accommodating both fiat and cryptocurrencies. Led by an experienced and dedicated team of business, finance, and technology veterans, INX shares a vision to redefine capital markets through blockchain technology and a disciplined regulatory approach.

LinkedIn: https://www.linkedin.com/company/theinxdigitalcompany/

X / Twitter: https://x.com/INX_Group

Website: https://www.inx.co/

About Backed

Backed brings real-world assets on-chain. Backed issues permissionless tokens that track the value of real-world assets and are fully collateralized by them, such as stocks or ETFs. Tokens are issued under an approved EU prospectus. Backed offers tokenization services to institutional clients, bridging the gap between TradFi and DeFi.

The Backed Assets (JE) bNVDA (ticker symbol: bNVDA) is a tracker certificate issued as an ERC-20 token, which tracks the price of the NVIDIA Corp.

Backed’s tracker products (bTokens) are not offered, sold, or delivered within the United States, or for the account or benefit of U.S. Persons. For a full list of prohibited and restricted countries, and to review legal documentation, please visit https://www.assets.backed.fi/legal-documentation

LinkedIn: https://www.linkedin.com/company/backed-finance/

X / Twitter: https://twitter.com/backedfi

Website: https://backed.fi/

 

 

 

 

Contact

MarketAcross
[email protected]

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Equasens: 2024 half-year results

2024-09-27T16:00:00Z

Villers-lès-Nancy, 27 September 2024 - 6:00 p.m. (CET)

PRESS RELEASE

2024 half-year results

  • Group results impacted by weaker economic conditions and continuing investment efforts in H1:
    • Revenue: €108.0m, -4.1%
    • Current Operating Income: €20.9m, -24.1%
  • Net Profit attributable to the Group: €17.2m, -21.8%
  • Though with a profit margin that continues to be very positive:
    • Ratio of Current Operating Income (COI) to Sales: 19.3% on a reported basis and 20.0% like-for-like
H1 RESULTS (€M)2023
reported basis
2024
reported basis
Change / Reported basisExternal growthChange / Like-for-like basis
Revenue112.6108.0-4.6-4.1%-3.7-8.3-7.4%
Current operating income (COI)27.520.9-6.6-24.1%0.0-6.7-24.3%
Net Profit22.918.1-4.8-21.0%0.0-4.8-21.1%
Net Profit attributable to the Group22.017.2-4.8-21.8%   

The financial statements for the six-month period ended 30 June 2024 were reviewed and adopted by EQUASENS' Board of Directors, chaired by Thierry Chapusot, on 27 September 2024. These interim consolidated financial statements were subject to a limited review by the Statutory Auditors.

_____

Results at 30 June 2024

H1 Current Operating Income / Division2023
reported basis
2024
reported basis
Change / Reported basisExternal growthChange / Like-for-like basis
Pharmagest18.414.1-4.3-23.5%-0.1-4.4-24.0%
Axigate Link4.64.4-0.2-4.9% -0.2-4.9%
e-Connect3.62.5-1.1-29.9% -1.1-29.9%
Medical Solutions1.30.0-1.3-100.0%0.1-1.2-92.5%
Fintech-0.4-0.10.369.3% 0.3-69.3%
Current Operating Income27.520.9-6.6-24.1%0.0-6.7-24.3%
  • PHARMAGEST division: a contraction in earnings reflecting lower sales and reinforced teams in Europe (COI/Sales: 17.2%)

The decline in the Division's operating income is mainly attributable to a reduction in sales in France in the configuration and hardware segment. In a persistently challenging economic environment, the Division continued to focus its commercial strategy on acquiring new customers and regularly rolling out new software and hardware solutions.
Despite this, recurring revenues were bolstered by the combined contribution of new SaaS offerings and contract indexation.
To accelerate the deployment of solutions in Europe, the R&D and sales teams continued to be strengthened.

  • AXIGATE LINK division: the profit margin remains high (COI/Sales: 28.6%)

Strategic investments to support the roll-out of SaaS solutions such as TitanLink for Nursing Homes in Europe, and the extension of homecare services, have temporarily weighed on the Division's results.

  • E-CONNECT division: current operating income declined in response to lower sales (COI/Sales: 45.4%)

As previously reported, H1 2023 sales and earnings were boosted by the announced discontinuation of sales of Application Reader Terminals.
The downturn in business in the first half of 2024 thus reflected the corresponding decline in sales.
Despite this unfavourable environment, the Division demonstrated its ability to adapt by maintaining a healthy profit margin based on tight cost controls.

  • MEDICAL SOLUTIONS division: a year of transition between the Ségur digital healthcare investment programme and a new software solution (COI/Sales: -)

Preparations for the Division's future involving the development of a new software platform and optimising the sales organisation led to significant investments which, in conjunction with lower sales following the end of the Ségur programme roll-out, weighed on the Division's results. Recurring revenues rose 13.7%, resulting in a gross margin of 72.8%.

  • FINTECH division: efforts to stabilise the business paid off in H1, with an improvement in earnings of €0.3m (COI/Sales: -)

Consolidated balance sheet highlights

  • Cash flow after interest and tax maintained a positive trend at €20.8m.
  • Financial investments, through acquisitions as well as capital expenditures, in particular for the EQUASENS private healthcare cloud, continued, with more than €16.0m committed in H1.
  • The net financial surplus at 30/06/2024 of €87.9m takes into account a change in presentation of IFRS 16 lease liabilities and put options for minority shareholders of €10.8m (recognised under other liabilities versus financial liabilities previously).

2024 outlook

  • The Group maintains its forecast for a return to revenue growth starting in the second half of 2024, and an acceleration in 2025 driven by current investments and an economic climate that looks set to improve, particularly for pharmacies in France.
  • The Group will continue to invest in R&D, infrastructure and sales forces in France and Europe in the second half of 2024. And while this will have a temporary impact on profitability in 2024, it should generate a return on investment from 2025 onwards.
  • With a strategy focused on patients and interoperability, the Group is ideally positioned to seize opportunities for external growth in France and Europe.

Financial calendar:

  • 1 October 2024: Presentation of H1 2024 results
  • 7 November 2024: Publication of Q3 2024 revenue
  • 6 February 2025: Publication of f Q4/FY 2024 revenue

About Group Equasens

With more than 1,300 employees, Equasens Group is today a key player in the European healthcare sector, providing software and hardware solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, hospital-at-home programmes, retirement homes, health centres) in both primary and secondary care sectors.

With operations in in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group today brings together healthcare professionals within a unique ecosystem in France and Europe benefiting people by making available the very best of technology.

Listed on Euronext Paris™ - Compartment B

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).
ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about Equasens Group www.equasens.com and on LinkedIn

CONTACTS

Analyst and Investor Relations:
Chief Administrative and Financial Officer: Frédérique Schmidt
Tel: +33 (0)3 83 15 90 67 - [email protected]

Financial communication agency:
FIN’EXTENSO - Isabelle Aprile

Tel.: +33 (0)6 17 38 61 78 - [email protected]

Attachment


GlobeNewsWire News

Recent Comments